Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder
After PGx testing, patients with MDD had decreased prescribing of medications with significant GDI and reduced HRU. PGx testing may have influenced these outcomes, but the retrospective study design limits clarity on its impact.
Authors
- Alexander Gutin (ORCID: https://orcid.org/0000-0002-6565-3729)
- Devika Chawla (ORCID: https://orcid.org/0000-0001-9785-3525)
- Andria L. Del Tredici (ORCID: https://orcid.org/0000-0002-9746-7728)
- Katherine Johansen Taber (ORCID: https://orcid.org/0000-0003-3051-2667)
- Pamela Morin
- Laura Becker (ORCID: https://orcid.org/0000-0002-2023-7609)
- Andrew A. Nierenberg
- Holly L. Johnson (ORCID: https://orcid.org/0000-0001-7080-5638)
- Brady DeHart
- Chelsea R. Kasten
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- Optum (United States) (US)
- Myriad Genetics (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1097/jcp.0000000000001999
- Citations
- 7
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 8.37